申请人:The DuPont Merck Pharmaceutical Company
公开号:US05849736A1
公开(公告)日:1998-12-15
This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
这项发明涉及新型异噁唑烷和异噁唑醇,其作为血小板糖蛋白IIb/IIIa纤维蛋白原受体复合物或维脱纳受体的拮抗剂,以及含有这些化合物的药物组合物,制备这些化合物的方法,以及使用这些化合物单独或与其他治疗剂联合用于抑制血小板聚集,作为溶栓剂,并/或用于治疗血栓栓塞性疾病。